

Parkinson's Disease

Lumantity and The PHARMO Institute delivers research insights into Parkinson's Disease.

Disease & treatment characterization

- Diagnosis
- Pathology
- Social demographics
- Anti-Parkinson's drug prescriptions

Healthcare resource utilization

- Multi-setting healthcare resource use
- In- and out-patient drug exposure data
 - Levodopa
 - Dopamine agonists
 - MOA-B inhibitors
 - Anticholinergics
 - COMT inhibitors
- Malignancy, pathology
- Social demographics

Predictors of early-stage disease

- Longitudinal data allows analysis of early predictors of disease
 - Family history
 - MCI (Mild Cognitive Impairment)
 - Short-term memory loss
 - Head traumas
 - Comorbidities (e.g., Cardiovascular Disease, Depression, Anxiety, Psychosis)



What makes us different



High patient counts in Parkinson's Disease

>16,000 Parkinson's Disease

- 4-year average follow-up
- 20-year average look-back



A unique, longitudinal, and clinically rich dataset

- 2002 onwards (20+ years)
- Ability to follow through multiple healthcare settings
- Data regularly updated and expanded to include new patients and follow-up information

About PHARMO



The PHARMO Institute is a **global leader** in drug safety and outcomes research



The Netherlands has an excellent healthcare system and is a major hub for clinical trials



Dutch data is **representative of Western Europe** and can be used in global studies as a robust proxy or complement to EU-5



PHARMO maintains an extensive network of data partners across NA and Europe. As a founding member of SIGMA Consortium, we can access diverse sources of **pan-European real world data (RWD) on >100 million patients**



Our capabilities and experience enable us to deliver on a **wide range of real world evidence (RWE) use cases**



⇒ Why choose us?

We can be counted on for service and quality. We utilize proven processes supported by technologically advanced resources to produce high-quality services, with guaranteed satisfaction.